Valtrate antagonizes malignant phenotypes of lung cancer cells by reducing SLC7A11

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Lung cancer (LC) remains a leading cause of cancer-related mortality worldwide.
• Identifying novel therapeutic agents targeting cancer cell proliferation and survival is crucial.
• Valtrate (Val) is a natural compound with potential anti-cancer properties.

Purpose of the Study:

• To investigate the efficacy of valtrate (Val) as a potential therapeutic agent against lung cancer (LC).
• To elucidate the underlying mechanisms of Val's action, focusing on ferroptosis and SLC7A11.
• To evaluate Val's effects on lung cancer cells in vitro and in a xenograft mouse model.

Main Methods:

• Lung cancer cell lines (A549, H1299) were treated with Val, with SLC7A11 overexpression induced via transfection.
• Cell viability, proliferation, and apoptosis were assessed using CCK-8, EdU, and Annexin-V/propidium iodide staining.
• Ferroptosis, reactive oxygen species (ROS) levels, and protein expression (SLC7A11, GPX4) were analyzed.
• A xenograft mouse model was utilized to evaluate Val's in vivo efficacy.

Main Results:

• Val significantly reduced lung cancer cell viability and proliferation in a dose-dependent manner.
• Val treatment markedly increased apoptosis and ROS generation in cancer cells.
• Val decreased SLC7A11 and GPX4 expression while increasing intracellular iron levels (Fe2+).
• Overexpression of SLC7A11 counteracted the effects of Val, and in vivo studies showed reduced tumor volume and weight.

Conclusions:

• Valtrate demonstrates significant anti-lung cancer activity by inhibiting cell proliferation and inducing apoptosis.
• Val's mechanism involves the downregulation of SLC7A11, leading to ferroptosis.
• Val holds promise as a therapeutic agent for lung cancer, potentially by targeting the SLC7A11 pathway.